80
Participants
Start Date
September 30, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
NMD670
Tablets taken twice daily for 21 days
Placebo
Tablets taken twice daily for 21 days
University Hospitals Leuven, Department of Neurology, Leuven
CHR de la Citadelle- Site Citadelle Neurolgie Boulevard du 12eme de Ligne 1, Liège
Hospital Universitari Vall d'Hebron, Barcelona
Columbia University Medical Center, New York
CHU Marseille, Reference centre for neuromuscular diseases and ALS Department of Neuromuscular Diseases, Marseille
University of Rochester Neuromuscular Disease Center, Rochester
OSU Department of Neurology Division of Neuromuscular Diseases, Columbus
Hospital Universitari i Politecnic La Fe de Valencia, Valencia
NextGen Precision Health, Columbia
University of Kansas Medical Center, Department of Neurology, Kansas City
Institut de Myologie Groupe Hospitalier Pitié-Salpêtrière, Paris
National Neuromuscular research Institute, PLLC, Austin
Bicêtre University Hospital, Paris
Providence Medical Research Center, Spokane
Mass General Neurology, Boston
Aarhus University Hospital, Aarhus
Rigshospitalet, Department of Neurology, Copenhagen
Laboratoire d'Explorations Fonctionnelles, CHU Nantes, Nantes
Centre Hospitalier Universitaire De Nice, Nice
Lead Sponsor
NMD Pharma A/S
INDUSTRY